These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 23899748)

  • 1. Aldosterone glucuronidation inhibition as a potential mechanism for arterial dysfunction associated with chronic celecoxib and diclofenac use in patients with rheumatoid arthritis.
    Crilly MA; Mangoni AA; Knights KM
    Clin Exp Rheumatol; 2013; 31(5):691-8. PubMed ID: 23899748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-steroidal anti-inflammatory drug (NSAID) related inhibition of aldosterone glucuronidation and arterial dysfunction in patients with rheumatoid arthritis: a cross-sectional clinical study.
    Crilly MA; Mangoni AA
    BMJ Open; 2011 May; 1(1):e000076. PubMed ID: 22021751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
    Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
    Kellner HL; Li C; Essex MN
    Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
    Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
    Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physical inactivity and arterial dysfunction in patients with rheumatoid arthritis.
    Crilly MA; Wallace A
    Scand J Rheumatol; 2013; 42(1):27-33. PubMed ID: 22839595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
    Whelton A; Lefkowith JL; West CR; Verburg KM
    Kidney Int; 2006 Oct; 70(8):1495-502. PubMed ID: 16941030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upper gastrointestinal tolerability of celecoxib compared with diclofenac in the treatment of osteoarthritis and rheumatoid arthritis.
    McKenna F; Arguelles L; Burke T; Lefkowith J; Geis GS
    Clin Exp Rheumatol; 2002; 20(1):35-43. PubMed ID: 11892706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.
    Gislason GH; Jacobsen S; Rasmussen JN; Rasmussen S; Buch P; Friberg J; Schramm TK; Abildstrom SZ; Køber L; Madsen M; Torp-Pedersen C
    Circulation; 2006 Jun; 113(25):2906-13. PubMed ID: 16785336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF; Hsiao FY; Wen YW; Tsai YW
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between nonnaproxen NSAIDs, COX-2 inhibitors and hospitalization for acute myocardial infarction among the elderly: a retrospective cohort study.
    Rahme E; Watson DJ; Kong SX; Toubouti Y; LeLorier J
    Pharmacoepidemiol Drug Saf; 2007 May; 16(5):493-503. PubMed ID: 17086567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.
    Emery P; Zeidler H; Kvien TK; Guslandi M; Naudin R; Stead H; Verburg KM; Isakson PC; Hubbard RC; Geis GS
    Lancet; 1999 Dec 18-25; 354(9196):2106-11. PubMed ID: 10609815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amelioration of small bowel injury by switching from nonselective nonsteroidal anti-inflammatory drugs to celecoxib in rheumatoid arthritis patients: a pilot study.
    Inoue T; Iijima H; Arimitsu J; Hagihara K; Kawai S; Shiraishi E; Hiyama S; Mukai A; Shinzaki S; Nishida T; Ogata A; Tsujii M; Takehara T
    Digestion; 2014; 89(2):124-32. PubMed ID: 24526219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
    Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
    N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial stiffness and cumulative inflammatory burden in rheumatoid arthritis: a dose-response relationship independent of established cardiovascular risk factors.
    Crilly MA; Kumar V; Clark HJ; Scott NW; Macdonald AG; Williams DJ
    Rheumatology (Oxford); 2009 Dec; 48(12):1606-12. PubMed ID: 19858120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs.
    Mallen SR; Essex MN; Zhang R
    Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
    Goldstein JL; Chan FK; Lanas A; Wilcox CM; Peura D; Sands GH; Berger MF; Nguyen H; Scheiman JM
    Aliment Pharmacol Ther; 2011 Oct; 34(7):808-16. PubMed ID: 21810115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.